Studies recently closed to accrual | awaiting results
OBLIQUE | UK PI John Ramage [NCRN572]
A Phase IV, Observational study to assess Quality of Life in patients with pNETs receiving treatment with oral 10 mg Everolimus (Afinitor®) o.d.
This prospective, observational, study evaluated quality of life (through the use of patient-reported outcomes) of patients with well-differentiated pancreatic neuroendocrine tumours (pNETs) who were receiving everolimus as part of their standard care. A total of 44 UK patients were recruited.
LUNA | UK PI Tim Meyer [NCRN574][NCT01563354]
Multicenter 3-arm trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymus
This study closed to accrual having recruited ahead of target; 20 patients were recruited in the UK. Results of the study are expected in late 2016/early 2017.